The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 5, 2006, Pages 577-583

  Ogata, Yutaka ^a   Matono, Keiko ^a   Sasatomi, Teruo ^a   Ishibashi, Nobuya ^a   Ohkita, Akira ^a   Mizobe, Tomoaki ^a   Ogo, Shujiro ^a   Ikeda, Satoru ^a   Ozasa, Hiroyuki ^a   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal carcinoma; Immunohistochemistry; MMP 9 expression; Molecular targeting therapy for MMP; Oral fluoropyrimidine; Postoperative adjuvant chemotherapy

Indexed keywords

DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; GELATINASE B; TUMOR MARKER; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PHARMACODYNAMICS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 32544460436     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0081-9     Document Type: Article

References (34)

1. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer Statistics. CA Cancer J Clin 50:7-33
2. International Multicentric Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-944
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
4. Sakamoto J, Kato J, Nakazato H (2000) Adjuvant chemotherapy clinical trials against colorectal cancer in Japan. Jpn J Cancer Clin 46:1187-1195
5. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer (2004) Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22:484-492
6. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R (2004) A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22: 3508
7. Twelves C, Wong A, Nowacki MP, McKendrick J, Van Hazel G, Douillard J-Y, Diaz-Rubio E, Cassidy J, Maroun J (2005) Updated efficacy findings from the X-ACT phase III trial of capecitabine vs. bolus 5-FU/LV as adjuvant therapy for patients with Dukes' C colon cancer. Proc Am Soc Clin Oncol (abstract 3521)
8. Inuzuka K, Ogata Y, Nagase H, Shirouzu K (2000) Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 93:211-218
9. 9. Ogata Y, Pratta MA, Nagase H, Arner EC (1992) Matrix metalloproteinase 9 (92-kDa) gelatinase/type IV collagenase) is induced in rabbit articular chondrocytes by cotreatment with interleukin 1β and a protein kinase C activator. Exp Cell Res 201:245-249
10. Shirouzu K, Isomoto H, Morodomi T, Kakegawa T (1995) Carcinomatous lymphatic permeation: prognostic significance in patients with rectal carcinoma - a long term prospective study. Cancer 75: 4-10
11. Shirouzu K, Isomoto H, Kakegawa T, Morimatsu M (1991) A prospective clinicopathologic study of venous invasion in colorectal cancer. Am J Surg 162:216-222
12. International Multicentric Pooled Analysis of B2 Colon Cancel-Trials (IMPACT B2) investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356-1363
13. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) CPT-11 Gastrointestinal Cancer Study Group: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913
14. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-Andre G, Rougier P (1998) Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16:2739-2744
15. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914
16. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
17. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292
18. Seitz JF (2001) 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer. Semin Oncol 28(suppl 1):41-44
19. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559
20. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250
21. Dancey JE, Freidlin B (2003) Targeting epidermal growth factor receptor - Are we missing the mark? Lancet 362:62-64
22. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase 1 studies. J Clin Oncol 21:3955-3964
23. Stetler-Stevenson WG (1990) Type IV collageneses in tumor invasion and metastasis. Cancer Metastasis Rev 9:289-303
24. Liotta L, Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion. Semin Cancer Biol 1:99-106
25. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270
26. Zucker S, Conner C, DiMassmo BI, Ende H, Drews M, Seiki M, Bahou WF (1995) Thrombin induces the activation of progelatinase A in vascular endothelial cells: physiologic regulation of angiogenesis. J Biol Chem 270:23730-23738
27. Jadhav U, Chigurupati S, Lakka SS, Mohanam S (2004) Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol 25:1407-1414
28. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48:411-424
29. Yamauchi K, Ogata Y, Nagase H, Shirouzu K (2001) Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg Today 31:791-798
30. Oba K, Konno H, Tanaka T, Baba M, Kamiya K, Ohta M, Kaneko T, Shouji T, Igarashi A, Nakamura S (2002) Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett 175:45-51
31. Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L (2004) An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/ leucovorin. Invest New Drugs 23:63-71
32. Eatock M, Cassidy J, Johnson J (2005) A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 55:39-46
33. Maki H, Hojo K, Tanaka H, Sawada TY, Maekawa R, Yoshioka T (2002) Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11. Clin Exp Metastasis 19:519-526
34. Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Oba K, Kaneko T, Syouji T, Igarashi A, Nakamura S (2001) Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Jpn J Cancer Res 92:688-695